Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information
Registry Information

Alternate Title

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	18 and over	Other	CAN-NCIC-IND137 NCI-NCIC-137, NCT00005971, NCIC-137, IND137

Objectives

1. Assess the efficacy of flavopiridol in patients with previously untreated metastatic malignant melanoma.
2. Assess the toxicity of this treatment in these patients.
3. Assess the time to progression, early progression rate, and response duration in these patients when treated with this regimen.

Entry Criteria

Disease Characteristics:

• Histologically confirmed metastatic malignant melanoma not amenable to standard curative therapies
  • No prior regional or systemic therapy for metastatic disease



• Measurable disease
  • At least 20 mm by conventional techniques

    OR

  • At least 10 mm by spiral CT scan
  • Bone lesions not considered measurable



• No known CNS metastases

Prior/Concurrent Therapy:

Biologic therapy:

• At least 4 weeks since prior adjuvant immunotherapy allowed
• No prior immunotherapy for metastatic disease

Chemotherapy:

• No prior chemotherapy for metastatic disease
• No other concurrent chemotherapy

Endocrine therapy:

• At least 4 weeks since prior adjuvant hormonal therapy

Radiotherapy:

• At least 4 weeks since prior radiotherapy and recovered
• Must have measurable disease outside irradiated area

  OR

• Evidence of progression or new lesions in irradiated area
• No more than 25% of functioning bone marrow irradiated
• No concurrent radiotherapy to sole site of measurable disease

Surgery:

• At least 4 weeks since prior major surgery

Other:

• No other concurrent anticancer therapy or investigational anticancer agents

Patient Characteristics:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• Absolute granulocyte count at least 1,500/mm3
• Platelet count at least 100,000/mm3

Hepatic:

• Bilirubin no greater than upper limit of normal (ULN)
• AST no greater than 2.5 times ULN

Renal:

• Creatinine no greater than ULN

Cardiovascular:

• If history of cardiac disease, ejection fraction greater than 50%
• No clinically significant cardiac symptomology

Pulmonary:

• If history of pulmonary disease, FEV1, FVC, and TLC greater than 60% predicted and DLCO greater than 50% predicted
• No clinically significant pulmonary symptomology

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other concurrent serious disease

Expected Enrollment

A total of 15-30 patients will be accrued for this study within 12-18 months.

Outline

This is a multicenter study.

Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment continues every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks, and then every 3 months until disease progression or death.

Burdette-Radoux S, Tozer RG, Lohmann RC, et al.: Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22 (3): 315-22, 2004.[PUBMED Abstract]

Burdette-Radoux S, Tozer RG, Lohmann R, et al.: NCIC CTG phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND.137). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1382, 2002.

Trial Contact Information

Trial Lead Organizations

NCIC-Clinical Trials Group

Susan Burdette-Radoux, MD, Protocol chair		Ph: 514-398-1444

Registry Information
Official Title		A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients with Previously Untreated Metastatic Malignant Melanoma
Trial Start Date		2000-07-04
Registered in ClinicalTrials.gov		NCT00005971
Date Submitted to PDQ		2000-05-05
Information Last Verified		2002-11-20
NCI Grant/Contract Number		R24-CA77202

Back to Top